Evidence map›Paper›PMID 41700594›Full record

ArticleeLife2026

Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of

Jean-Mathieu Desveaux, Eric Faudry, Carlos Contreras-Martel, François Cretin, Leonardo Sebastian Dergan-Dylon, Axelle Amen, Isabelle Bally, Victor Tardivy-Casemajor, Fabien Chenavier, Delphine Fouquenet and 4 more

Abstract read
In one paragraph

Article in eLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. EPY001, a Novel Monoclonal Antibody AgainstInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jean-Mathieu Desveaux *Univ. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.
Eric Faudry *Univ. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.ORCID https://orcid.org/0000-0001-9958-6029
Carlos Contreras-MartelUniv. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.
François CretinUniv. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.ORCID https://orcid.org/0000-0001-9939-0931
Leonardo Sebastian Dergan-DylonUniv. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.ORCID https://orcid.org/0000-0002-5355-7107
Axelle AmenUniv. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.ORCID https://orcid.org/0000-0002-0449-4445
Isabelle BallyUniv. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.ORCID https://orcid.org/0000-0002-8315-6080
Victor Tardivy-CasemajorUniv. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.ORCID https://orcid.org/0009-0002-4490-8769
Fabien ChenavierUniv. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.ORCID https://orcid.org/0009-0004-6438-0716
Delphine FouquenetCentre d'Étude des Pathologies Respiratoires INSERM U1100 - UFR de Médecine de Tours, Tours, France.
Yvan CasparUniv. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.
Ina AttreeUniv. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.ORCID https://orcid.org/0000-0002-2580-764X
Andrea DessenUniv. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.ORCID https://orcid.org/0000-0001-6487-4020
Pascal PoignardUniv. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.ORCID https://orcid.org/0000-0002-0021-7192

Funding

Agence Nationale de la Recherche 22-CE18-0009-02Agence Nationale de la Recherche ANR-10-INBS-0005-02Agence Nationale de la Recherche ANR-17-EURE-0003Region Auvergne Rhones Alpes 183360
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingPseudomonas aeruginosaAdolescentAdultAntigens, BacterialBacterial ToxinsCrystallography, X-RayCystic FibrosisHumansMemory B CellsPore Forming Cytotoxic ProteinsPseudomonas InfectionsType III Secretion SystemsVirulence FactorsYoung AdultAntibodies, MonoclonalAntibodies, NeutralizingAntigens, Bacterialantigen V, PseudomonasBacterial ToxinsPore Forming Cytotoxic ProteinsType III Secretion SystemsVirulence FactorsAntibodybacteriaB cellhumaninfectious diseasemicrobiologyPseudomonas aeruginosaT3SSvirulence factors

Identifiers

PMID41700594
PMCPMC12912723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.